Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

Share Price is delayed by 15 minutes
Get Live Data
1.90    0.00 (0.00%)
Bid:
1.80
Ask:
2.00
Spread: 0.20 (11.111%)
Market Cap: £8.30m
RENX Live PriceLast checked at - London Stock Exchange

Intraday Renalytix Plc Share Chart

Holding(s) in Company

28 Oct 2025 16:04

RNS Number : 1715F
Renalytix PLC
28 October 2025
Β 

Β 

TR-1: Standard form for notification of major holdings

Β 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

Renalytix PLC

GB00BYWL4Y04

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

UBS Group AG - Investment Bank & Global Wealth Management

City and country of registered office (if applicable)

ZΓΌrich

Switzerland

4. Full name of shareholder(s) (if different from 3.) v

Name

UBS AG

City and country of registered office (if applicable)

London, United Kingdom

5. Date on which the threshold was crossed or reached vi:

27 October 2025

6. Date on which issuer notified (DD/MM/YYYY):

28 October 2025

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

5.172754%

0.000000%

5.172754%

22,605,901

Position of previous notification (if

applicable)

8.002628%

0.000000%

8.002628%

Β 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

Β (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BYWL4Y04

22,605,901

5.172754%

SUBTOTAL 8. A

22,605,901

5.172754%

Β 

Β 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

Β 

Β 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

Β 

SUBTOTAL 8.B.2

Β 

Β 

Β 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

X

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

UBS Group AG

UBS AG

5.172754%

5.172754%

Β 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi

Β 

Place of completion

Zurich, Switzerland

Date of completion

28.10.2025

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
HOLFLFIRIVLTFIE
Date   Source Headline
27th Jun 20251:09 pmRNSHolding(s) in Company
26th Jun 202511:48 amRNSHolding(s) in Company
17th Jun 20257:00 amRNSkidneyintelX.dkd data presented at ERA Congress
3rd Jun 20257:00 amRNSGrowing collaboration with NYKHM
30th May 202512:38 pmRNSHolding(s) in Company
29th May 202512:35 pmRNSHolding(s) in Company
27th May 202512:43 pmRNSHolding(s) in Company
20th May 20257:00 amRNSFirst use of KidneyIntelX in new CKD therapy trial
16th May 20253:10 pmRNSHolding(s) in Company
29th Apr 202511:03 amRNSHolding(s) in Company
22nd Apr 202512:47 pmRNSHolding(s) in Company
17th Apr 20252:56 pmRNSHolding(s) in Company
17th Apr 20257:00 amRNSHolding(s) in Company
16th Apr 20257:00 amRNSLate Breaking KidneyIntelX data show care impact
10th Apr 20257:00 amRNSQ3 Trading Update
9th Apr 20251:58 pmRNSHolding(s) in Company
7th Apr 202511:33 amRNSHolding(s) in Company
31st Mar 20251:21 pmRNSHolding(s) in Company
25th Mar 20252:59 pmRNSHolding(s) in Company
21st Mar 20251:34 pmRNSHolding(s) in Company
20th Mar 20254:19 pmRNSHolding(s) in Company
18th Mar 20257:00 amRNSHalf-year Report
12th Mar 202512:00 pmRNSNotice of Interim Results & Investor Presentation
12th Feb 20251:46 pmRNSHolding(s) in Company
11th Feb 202512:52 pmRNSHolding(s) in Company
6th Feb 20257:00 amRNS-RPublication in journal (JASN) for kidneyIntelX.dkd
28th Jan 20251:26 pmRNSHolding(s) in Company
27th Jan 20257:00 amRNSTrading Update
17th Jan 20257:00 amRNSForeign Private Issuer re-qualification
30th Dec 20241:22 pmRNSGrant & Cancellation of Options
20th Dec 20244:27 pmRNSDirector/PDMR share purchase
19th Dec 202411:16 amRNSResult of AGM
19th Dec 20247:00 amRNSAGM Statement
17th Dec 20243:53 pmRNSHolding(s) in Company
11th Dec 202411:46 amRNSDirector/PDMR dealings
9th Dec 20245:27 pmRNSDirector/PDMR share purchase
6th Dec 20247:00 amRNSDirector/PDMR share purchase
4th Dec 202412:35 pmRNSDirector/PDMR share purchase
2nd Dec 20247:00 amRNSDirectorate Change
26th Nov 20242:06 pmRNSHolding(s) in Company
26th Nov 20247:00 amRNSPublication of Annual Report and Notice of AGM
25th Nov 20246:23 pmRNSHolding(s) in Company
21st Nov 20247:00 amRNSAudited Full Year Fiscal 2024 Results
20th Nov 20247:00 amRNSFinancial Results for Q1 of Fiscal Year 2025
8th Nov 20249:31 amRNSHolding(s) in Company
7th Nov 20244:35 pmRNSHolding(s) in Company
7th Nov 20241:20 pmRNSHolding(s) in Company
6th Nov 20242:25 pmRNSCancellation of Ordinary Shares & TVR
5th Nov 20247:00 amRNSDirectorate Change
5th Nov 20247:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.